Orum Therapeutics Appoints Chad May as Chief Scientific Officer to Drive Degrader-Antibody Conjugate Innovation and Programs ...

Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody ...

You may have heard of the consulting firm Gartner’s technology hype cycle—the technology trigger, the peak of inflated expectations, the trough of disillusionment, the slope of enlightenment, and the ...

Harbour BioMed, a global biopharmaceutical company, has entered a long-term strategic collaboration with Yantai Lannacheng Biotechnology Co., Ltd.

The conjugate space is evolving fast - moving beyond traditional ADCs into new formats like degrader-conjugates, oligonucleotide conjugates, bispecific ADCs, and more. The 4 th Novel Conjugates Summit ...

Radionuclide drug conjugates (RDCs) have emerged as transformative agents that integrate diagnosis and therapy into a single ...

Antibody-drug conjugates are a new kind of targeted treatment for multiple myeloma. They deliver powerful cancer-killing drugs straight to myeloma cells, and they help your own immune system attack ...

In the face of booming antibody market, China has jumped into the antibody-drug conjugate space. Jin Zhang reports. In the recent years, antibody-drug conjugates (ADC) have been gradually gaining ...

Genitourinary oncologist Jonathan Rosenberg says two newer classes of bladder cancer drugs are greatly expanding treatment options for the disease. Promising new drugs have begun to transform the ...

Infectious diseases remain a major health threat, as demonstrated by the emergence of COVID-19, which to date, is responsible for more than one million deaths globally. The ongoing evolution of viral ...